By succeeding to launch at least one distinctive product each year, Nippon Shinyaku (4516 JP) increased both revenue and operating profit for nine fiscal years in a row.
The company’s new drug Viltepso, targeting 8% of Duchenne muscular dystrophy patient population has an estimated peak sale of more than $400 million.
By FY24, the company plans to launch one new in-house drug for myelofibrosis, which is preparing to go for phase 2 trial.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.